Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 220.00
Ask: 230.00
Change: 10.00 (4.65%)
Spread: 10.00 (4.545%)
Open: 215.00
High: 234.00
Low: 225.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron files patent application for Traumakine

1 Mar 2016 07:00

RNS Number : 5448Q
Faron Pharmaceuticals Oy
01 March 2016
 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

 

Faron files patent application to further strengthen protection for its novel Traumakine®

(FP-1201-lyo) formulation

 

TURKU - FINLAND, 1 March 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the drug discovery and development company is pleased to announce that it has filed a national application for a new formulation patent in Finland with filings to be expanded over the next two years to almost all countries worldwide under the Patent Co-operation Treaty (PCT). The patent further protects Faron's final FP-1201-lyo (lyophilised interferon-beta or Traumakine®) formulation for the intravenous treatment of acute respiratory distress syndrome ("ARDS") and other vascular diseases.

Interferon-beta, especially if freeze-dried, is known to form aggregates or stick to container surfaces, requiring careful control of dosing and in-use stability during administration. Faron has developed a proprietary new product formulation for which tests have shown almost 100 per cent recovery of solubilised interferon-beta for intravenous use. With this patent formulation filing, Faron is seeking to protect this discovery for the next 20 years. Based on patent database searches, no similar formulation has been reported previously.

Dr Markku Jalkanen, CEO of Faron, said: "As of today, our Traumakine treatment is the only known intravenously administered human interferon-beta preparation and it is important that dosing is optimal for patients lacking peripheral circulation, as is the case with ARDS patients. We have carefully tested various ingredients to optimise interferon-beta use in these patients and have now completed all necessary tests for patent purposes. If our claims are approved, we could have a proprietary product for the next two decades, further increasing Traumakine's significant, commercial potential. We already have new use patents for interferon-beta in ischaemic conditions and multi organ failure, and this new formulation patent will reinforce our global patent protection strategy".

The new formulation, which has not previously been made public, is already in use in Faron's pivotal, pan-European INTEREST trial, the recruitment of which the Company expects to be completed in 10-16 months from now. Besides several granted patents and pending filings, Faron has also sought exclusivity for Traumakine through orphan drug designations (ODD) and has been successful in Europe regarding ARDS. The Company has also sought ODD in the USA where the application is ongoing. Faron's Japanese licensing partner Maruishi Pharmaceutical, Co. is also planning to file an orphan application in Japan.

 

For more information contact:

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone +358 (50) 577 4807E-mail: katja.wallenlind@faronpharmaceuticals.com

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

 

Whitman Howard Limited, Nominated Broker

Niall Devins, Francis North

Phone: +44 207 659 1234

 

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

 

About Faron Pharmaceuticals Ltd

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. Faron is based in Turku, Finland. The Company has identified several molecular mechanisms involved in the control of endothelial functions as a source of innovations. Faron currently has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition for which there is currently no approved pharmaceutical treatment. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating representing a novel immuno-oncology approach.

Further information is available at www.faronpharmaceuticals.com.

About Traumakine®

Faron completed a Phase I/II trial in respect of Traumakine® in 2011 where treatment with Traumakine® was associated with an 81% reduction in the odds of 28 day mortality in patients with ARDS. These data were published in The Lancet Respiratory Medicine, a leading medical journal (Bellingan et al. 2014).

The scientific rationale for Traumakine® treatment is based on the proprietary use of room temperature stable formulation of interferon-beta-1a (FP-1201-lyo) for the restoration of the endothelial barrier function in ARDS patients. In Phase I/II trials interferon-beta was found to be safe and well tolerated in ARDS patients and the optimal tolerated dose was established. The selected pharmacodynamic marker for interferon-beta bioactivity showed clear dose response and the treatment target molecule CD73 levels were induced during the dosing period.

The Traumakine® research consortium (www.traumakine.eu) led by Faron has received €6 million funding from the European Union Seventh Framework Programme (FP7) targeting European marketing application as a final milestone of the programme.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUKARRNBAUUUR
Date   Source Headline
18th Feb 202011:06 amRNSSecond Price Monitoring Extn
18th Feb 202011:00 amRNSPrice Monitoring Extension
18th Feb 20209:05 amRNSSecond Price Monitoring Extn
18th Feb 20209:00 amRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTraumakine update
27th Jan 20207:00 amRNSOvarian cancer selected as 2nd MATINS trial cohort
13th Jan 20207:00 amRNSDMC approves colorectal cancer cohort expansion
30th Dec 20199:30 amRNSUpdate on Traumakine drug substance manufacturing
12th Dec 20192:00 pmRNSPrice Monitoring Extension
11th Dec 20197:00 amRNSMatins Trial Update
2nd Dec 20192:06 pmRNSSecond Price Monitoring Extn
2nd Dec 20192:00 pmRNSPrice Monitoring Extension
29th Nov 20192:05 pmRNSSecond Price Monitoring Extn
29th Nov 20192:00 pmRNSPrice Monitoring Extension
29th Nov 20197:31 amRNSLIQUIDITY PROVIDING AGREEMENT
29th Nov 20197:30 amRNSCompany Description & information on cash position
28th Nov 20199:05 amRNSSecond Price Monitoring Extn
28th Nov 20199:00 amRNSPrice Monitoring Extension
28th Nov 20197:00 amRNSFDA has approved Faron's Clevegen IND
27th Nov 20194:00 pmRNSFaron´s financial calendar for 2020
21st Nov 20192:00 pmRNSHoldings in Company
21st Nov 20199:00 amRNSPrice Monitoring Extension
21st Nov 20197:15 amRNSApplication to Nasdaq First North Growth Market
19th Nov 201911:05 amRNSSecond Price Monitoring Extn
19th Nov 201911:00 amRNSPrice Monitoring Extension
15th Nov 201911:06 amRNSSecond Price Monitoring Extn
15th Nov 201911:00 amRNSPrice Monitoring Extension
12th Nov 20193:45 pmRNSRegistration of Shares
8th Nov 20197:00 amRNSResults of Placing and Issue Price
7th Nov 20194:51 pmRNSProposed Placing and Financial Adviser Appointment
5th Nov 20194:40 pmRNSSecond Price Monitoring Extn
5th Nov 20194:36 pmRNSPrice Monitoring Extension
5th Nov 20192:05 pmRNSSecond Price Monitoring Extn
5th Nov 20192:00 pmRNSPrice Monitoring Extension
5th Nov 201911:05 amRNSSecond Price Monitoring Extn
5th Nov 201911:00 amRNSPrice Monitoring Extension
5th Nov 20199:05 amRNSSecond Price Monitoring Extn
5th Nov 20199:00 amRNSPrice Monitoring Extension
4th Nov 20194:35 pmRNSPrice Monitoring Extension
4th Nov 20192:05 pmRNSSecond Price Monitoring Extn
4th Nov 20192:00 pmRNSPrice Monitoring Extension
1st Nov 20192:15 pmRNSStatement regarding Price Movement
1st Nov 20192:05 pmRNSSecond Price Monitoring Extn
1st Nov 20192:00 pmRNSPrice Monitoring Extension
1st Nov 201911:06 amRNSSecond Price Monitoring Extn
1st Nov 201911:00 amRNSPrice Monitoring Extension
31st Oct 20194:35 pmRNSPrice Monitoring Extension
25th Oct 20199:27 amRNSResults of EGM
11th Oct 20192:05 pmRNSSecond Price Monitoring Extn
11th Oct 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.